Suppr超能文献

抗代谢物效应的调节。胸苷对喹唑啉类胸苷酸合成酶抑制剂CB3717疗效的影响。

Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.

作者信息

Jackman A L, Taylor G A, Calvert A H, Harrap K R

出版信息

Biochem Pharmacol. 1984 Oct 15;33(20):3269-75. doi: 10.1016/0006-2952(84)90089-3.

Abstract

CB3717 (N-(4-(N-((2-amino-4- hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino ) benzoyl)-L-glutamic acid) is an antitumour agent that inhibits thymidylate synthetase (TS). A dose-dependent fall in plasma thymidine (dThd) (1.43 microM to 0.47 microM) occurred in non-tumour-bearing mice following the administration of CB3717. Further, in mice carrying the L1210/CBRI tumour, the drug's antitumour properties were ablated by co-administration of dThd, an effect consistent with TS being the cytotoxic locus. In vitro studies of protection by dThd against CB3717 cytotoxicity were carried out in an attempt to quantify this reversal. The metabolism of [14C]-dThd was measured in cultures of L1210 cells (10(4)/ml) exposed to a completely cytotoxic dose of CB3717 (50 microM). The cytotoxicity of the drug was only expressed when the dThd concentration (0.5-2 microM) had fallen to less than 0.1 microM in the media. This reduction was due to: (1) dThd incorporation into DNA, (2) catabolism of dThd to thymine. By reducing the initial cell concentration to 10(3)/ml the depletion of dThd was substantially reduced and consequently cells continued to grow for a longer period. The critical concentration of dThd, below which growth in the presence of CB3717 could not be supported was estimated to be between 0.026 and 0.1 microM. Thus even the minimum level of dThd achieved in vivo was still in excess of that required for protection from CB3717 toxicity in vitro. There was a small accumulation of deoxyuridine (dUrd) (approximately 2-fold) in mouse plasma 24 hr after completion of a 5-day course of CB3717 (200 mg/kg) but in vitro studies demonstrated that this was unlikely to modulate CB3717 toxicity in the presence of dThd. We caution against the use of rodent tumour models (or human tumour xenografts) for antitumour or toxicity testing of compounds designed to inhibit the de novo synthesis of thymidylate; they may be misleading because the high dThd levels found in these animals compared with man may mask the cytotoxic effects of these drugs.

摘要

CB3717(N-(4-(N-((2-氨基-4-羟基-6-喹唑啉基)甲基)丙-2-炔基氨基)苯甲酰基)-L-谷氨酸)是一种抑制胸苷酸合成酶(TS)的抗肿瘤药物。给无瘤小鼠施用CB3717后,血浆胸苷(dThd)出现剂量依赖性下降(从1.43微摩尔降至0.47微摩尔)。此外,在携带L1210/CBRI肿瘤的小鼠中,同时施用dThd可消除该药物的抗肿瘤特性,这一效应与TS是细胞毒性位点一致。为了量化这种逆转作用,进行了dThd对CB3717细胞毒性的体外保护研究。在暴露于完全细胞毒性剂量的CB3717(50微摩尔)的L1210细胞(10⁴/毫升)培养物中测量[¹⁴C]-dThd的代谢。只有当培养基中的dThd浓度(0.5 - 2微摩尔)降至低于0.1微摩尔时,该药物的细胞毒性才会表现出来。这种降低是由于:(1)dThd掺入DNA,(2)dThd分解代谢为胸腺嘧啶。将初始细胞浓度降低至10³/毫升可大幅减少dThd的消耗,因此细胞能够继续生长更长时间。估计dThd的临界浓度在0.026至0.1微摩尔之间,低于该浓度则无法支持在CB3717存在下的生长。因此,即使在体内达到的dThd最低水平仍超过体外免受CB3717毒性所需的水平。在完成5天疗程的CB3717(200毫克/千克)后24小时,小鼠血浆中脱氧尿苷(dUrd)有少量积累(约2倍),但体外研究表明,在存在dThd的情况下,这不太可能调节CB3717的毒性。我们提醒不要使用啮齿动物肿瘤模型(或人肿瘤异种移植模型)对旨在抑制胸苷酸从头合成的化合物进行抗肿瘤或毒性测试;它们可能会产生误导,因为与人类相比,这些动物中发现的高dThd水平可能掩盖这些药物的细胞毒性作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验